Natera (NASDAQ:NTRA) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Wednesday.
Several other analysts also recently issued reports on the company. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Canaccord Genuity restated a “buy” rating and issued a $15.00 price objective on shares of Natera in a research report on Tuesday, November 14th. Finally, Cowen restated a “buy” rating and issued a $12.00 price objective on shares of Natera in a research report on Thursday, December 21st. Three equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $14.50.
Shares of Natera (NASDAQ NTRA) opened at $9.17 on Wednesday. The company has a debt-to-equity ratio of 2.43, a current ratio of 1.85 and a quick ratio of 1.75. Natera has a 12-month low of $7.35 and a 12-month high of $14.76. The stock has a market capitalization of $497.36, a price-to-earnings ratio of -3.74 and a beta of 2.18.
Natera Company Profile
Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.